Alector lays off 17% of staff after phase 2 Alzheimer's drug fail
Nov 26, 2024 · Alector removed AL003 from its pipeline but continued work with AbbVie on AL002. Across both AL002 and AL003, the deal was worth up to $985.6 million in option …
Alector turns to layoffs as Alzheimer’s drug fails
Nov 26, 2024 · Alector recorded a net loss of $42 million during the third quarter. AL002 is an antibody drug designed to activate a protein found on the surface of certain cells made in the …
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in ...
Nov 25, 2024 · SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically …
Alector announces AL002 trial misses endpoint ... - Markets Insider
Nov 25, 2024 · Alector announced results from the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early …
Alector’s AbbVie-Partnered Alzheimer’s Program Fails Phase II ...
Nov 26, 2024 · Alector is kicking off a resource realignment effort that will include a workforce reduction. The biotech expects its current cash position to last it through 2026. ... BioSpace is …
Alector stock drops after Alzheimer’s drug fails in Phase II trial
Nov 26, 2024 · Alector’s internal pipeline suffered a blow as the Phase II INVOKE-2 trial evaluating its Alzheimer’s disease therapy, AL002, failed to meet the primary endpoint.. The …
Press Releases - Alector
Aug 29, 2024 · Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial
Nov 25, 2024 · Alector Contacts: Alector Katie Hogan 202-549-0557 [email protected]. 1AB (media) Dan Budwick 973-271-6085 [email protected]. Argot Partners (investors) …
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 …
Feb 8, 2024 · SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) and GSK plc (LSE/NYSE: GSK) today announced that the first patient …
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 …
Feb 8, 2024 · Alector’s immuno-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal …